Mitochondria in Heart Muscle Cells of Patients With Heart Failure
Studies heart muscle mitochondria from biopsies in adults with heart failure and coronary artery disease.
Key facts
- Who runs it
- Tomsk National Research Medical Center of the Russian Academy of Sciences
- Where
- Tomsk, RussiaSee the site
- Trial code
- Registry title
- Ultrastructural Characteristics of Mitochondria in Cardiomyocytes in Heart Failure
- Status
- Recruiting
- People taking part
- 45 people, planned
- Started
- 31 Mar 2023
- Expected to end
- Nov 2027
- Type of study
- Observational
- Treatments tested
- coronary artery bypass grafting
- Record updated
- 6 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart failure caused by reduced heart pumping, who have blocked heart arteries and are going to have coronary bypass surgery.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Heart failure with reduced or mildly reduced pumping (left ventricle ejection fraction below 50%); obstructive multivessel coronary atherosclerosis that needs coronary bypass surgery
Main reasons for not taking part
- Refusing bypass surgery or taking part in the study
- Heart surgery other than bypass (valves, aneurysm)
- Active cancer
- Implanted heart devices
- Type 1 or type 2 diabetes
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- The presence of HFrEF or HFmrEF (EF of LV <50%)
- Obstructive multivessel coronary atherosclerosis as an indication for cardiac surgical correction of coronary blood flow (coronary bypass surgery)
- Signed informed consent to participate in the study, separate consents for biomaterial sampling and genetic research
Who cannot take part
- Additional cardiac surgery other than coronary bypass surgery (valves, aneurysm)
- Oncological diseases in the active stage
- Infiltrative heart diseases (sarcoidosis, amyloidosis, accumulation diseases)
- Autoimmune diseases
- Acute infectious and exacerbations of chronic somatic diseases
- Type 1 or type 2 diabetes mellitus
- Contraindications to myocardial scintigraphy, cardiopulmonary stress test
- Impossibility of prescribing optimal drug therapy after cardiac surgery
- Severe renal dysfunction (GFR <30 ml/min/1.73 m2)
- Refusal of revascularization or participation in the study
- The presence of implanted devices (EX, AICD, CT)
Where in Russia
- Tomsk National Research Medical Center, Russian Academy of SciencesTomsk, RussiaContact: Elena A KuzhelevaTaking people
About the trial
What the trial wants to find out
According to modern concepts, mitochondrial dysfunction may be the fundamental basis for the development and progression of CHF, including in patients undergoing myocardial revascularization. The processes of mitochondrial fusion, division and mitophagy are aimed at maintaining cellular homeostasis. A change in the balance of these processes can lead to the accumulation of damaged organelles with impaired functions. In patients with CHF, dysfunctional mitochondria are characterized by size dispersion, crist disorganization, and localization changes relative to myofibrils.
Read full original descriptionShow less
At the same time, the topic of the influence of mitochondrial dysfunction on the prognosis and clinical course of CHF remains debatable today. Direct study of the structural and functional features of mitochondria in human cardiomyocytes is an extremely difficult task, and therefore, such studies are carried out extremely rarely and on very limited cohorts. In the planned study, due to the long time of the study material recruitment, the ultrastructure of mitochondria in a large cohort of patients, ranging from 45 to 60 people, will be studied.
The aim of this study is to study the association of mitochondrial dysfunction with the clinical course and outcomes of CHF of ischemic etiology, as well as to assess the degree of compliance of indirect criteria of mitochondrial dysfunction with direct ultrastructural characteristics of mitochondria in cardiomyocytes.
This single-center prospective cohort study will involve 45-60 patients. The patients will have biopsy samples taken from the right auricle, as well as blood collection and preservation and its derivatives. Electron microscopy of myocardial samples will be performed to assess the ultrastructure of mitochondria of cardiomyocytes. The results of a direct study of mitochondria will be compared with indirect signs of mitochondrial dysfunction: the registration of the phenomenon of increased leaching of radiopharmaceuticals from the myocardium, an increase in the number of copies of mitochondrial DNA and the concentration of cytochrome C in the blood, the affiliation of mitochondrial DNA to haplogroup K. The results obtained in each of the research tasks will have high scientific significance and publication potential.
Treatments tested
- coronary artery bypass grafting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Association of Ultrastructural Characteristics of Mitochondria in Cardiomyocytes and Signs of Mitochondrial Dysfunction With the Clinical Course and Outcomes of Heart Failure
- Plain-language title
- Mitochondria in Heart Muscle Cells of Patients With Heart FailureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 October 2026